Flamel Technologies SA

NASDAQ

- -

- -

- -

- -

- -

- -

Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology primarily in the United States, France, and Ireland. It owns and develops drug delivery platforms, such as Micropump that allows the development and marketing of modified and/or controlled release of solid, oral dosage formulations of drugs; and LiquiTime, which develops modified/controlled release of liquid formulations for patients having issues swallowing tablets or capsules. The company’s drug delivery platforms also comprise Trigger Lock that develops abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, which develops extended/modified release of injectable dosage formulations of drugs. Its lead products include Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection; Karbinal ER for the treatment of seasonal and perennial allergic rhinitis; AcipHex Sprinkle, a delayed-release capsule; Cefaclor, cephalosporin antibiotic to treat certain infections; Flexichamber, a prescription medical device; and Coreg CR, a non-selective antagonist used for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. In addition, the company has various proprietary pipeline products, which are in various stages of development comprising Sodium Oxybate for patients suffering from narcolepsy; Ibuprofen for the treatment of pain; Guaifenesin for the treatment of chest congestion; Exenatide for the treatment of type-2 diabetes; Hydromorphone for relief of moderate to severe pain. Flamel Technologies SA was founded in 1990 and is headquartered in Vénissieux, France.